Treatment of IgA Nephrophy with Low-dose Mycophenolate mofetil and Steroid_West China Medical Journal

Authors：

JIN Qiaoling ,  TAO Ye , YIN Heng , HU Zhangxue , YU xiao , WEI Mian.

Department of Nephrology, West China Hospital, Sichuan University, Chengdu, Sichuan 610041, P. R. China;

Corresponding?author：

TAO Ye, Email: jinqiaoling-601@163.com

Keywords：

IgA腎病; 霉酚酸酯; 治療

DOI：

10.7507/1002-0179.20130305

Video：

Export PDF Favorites Scan Get Citation

Abstract Full text Figures/Tables Video References Cited by

目的　回顧性觀察糖皮質激素聯合小劑量嗎替麥考酚酯（MMF）對IgA腎病的臨床療效及安全性。方法　 2010年9月－2012年9月在我科門診就診的28例IgA腎病患者接受了小劑量MMF聯合激素治療。醋酸潑尼松起始劑量為0.6 mg/（kg·d），MMF起始劑量為0.5～1.0 g/d，2～4周內調節藥物劑量使血藥濃度（MPA-AUC）維持在30～60 mg·h/L。治療前及治療后每月隨訪觀察血清肌酐、血清白蛋白、尿蛋白定性、24 h尿蛋白定量及藥物不良反應等指標。誘導期初定為6個月，若6個月未完全緩解（CR）則延長至9個月，總療程至少12個月，主要評價指標為誘導治療期的完全緩解率。結果　全部患者均完成了12個月的隨訪觀察，全組28例中CR 8例（28.6%），部分緩解（PR）14例（50.0%），未緩解（NR）6例（21.4%），總有效率78.6%。隨訪過程中，3例患者出現呼吸道感染，其中2例住院治療；2例患者出現尿路感染，1例患者出現腹瀉。結論　小劑量MMF治療IgA腎病安全、有效且能在一定程度上節省患者費用，可作為其他免疫抑制方案治療無效或復發時的一種治療選擇。

Citation： JIN Qiaoling,TAO Ye,YIN Heng,HU Zhangxue,YU xiao,WEI Mian.. Treatment of IgA Nephrophy with Low-dose Mycophenolate mofetil and Steroid. West China Medical Journal, 2013, 28(7): 978-983. doi: 10.7507/1002-0179.20130305 Copy

1.	Luetscher Jr JA, Deming QB, Harvey J, et al. Treatment of nephrosis with cortisone[J]. J Clin Invest, 1950, 29(12): 1576-1587.
2.	Vanderwoude FJ. Mycophenplate mofetil(RS 61443): nothing new under the sun or an important break-through in the field of transplantation? [J]. Nephrol Dial Transpl, 1995, 10(7): 1112-1115.
3.	Huang YF, Liu ZH, Huang HD, et al. Effects of mycophenolic acid on endothelial cells[J]. Int Immunopharmacol, 2005, 5(6): 1029-1039.
4.	Allison AC. Mechanisms of action of mycophenolate mofetil[J]. Lupus, 2005, 14(3): S2-S8.
5.	Apple GB, Radhakrishnan J, Ginzler EM. Use of mycophenolate mofetil in autoimmune and renal diseases[J]. Transplantation, 2005, 80(2): S265-S271.
6.	Mase BD, Oyen R, Claes K, et al. Mycophenolate mofetil in IgA nephropathy: Results of a 3-year prospective placebo-controlled randomized study[J]. Kidney Int, 2004, 65(5): 1842-1849.
7.	Trinidad PR, Meza L, Diaz OA. Mycophenolate mofetil treatment in primary glomerular diseases without response to conventional immunosuppressive agents[J]. J Am Soc Nephrol, 2003, 14(7): 800-812.
8.	Polenakovic M, Grcevska L, Dzikova S. Mycophenolate mofetil in treatment of idiopathic stages IIII-V membranous nephropathy[J]. Nephrol Dial Transpl, 2003, 18(6): 1233-1234.
9.	D’Amcio G. Natural history of idiopathic IgA nephropathy: the role of clinical and histological prognostic factors[J]. Am J Kidney Dis, 2002, 36(2): 227-37.
10.	Tang S, Tang A, Wong S, et al. Long–term study of mycophenolate mofetil treatment in IgA nephropathy[J]. Kidney Int, 2010, 77(6): 543-549.
11.	Groth C, Pichlmayr R, Sadek S, et al. Placebo-controlled study of mycophenolate mofetil combined with cyclosporine and corticosteroids for prevention of acute rejection[J]. Lancet, 1995, 345(8961): 1321-1325.
12.	Appel GB, Contreras G, Dooley MA, et al. mycophenolate mofetil versus cyclophosphamide for Induction Treatment of Lupus Nephritis[J]. J Am Soc Nephrol, 2009, 20(5): 1103-1112.
13.	陳香美, 陳仆, 蔡廣研, 等. 麥考酚酸酯治療IgA 腎病的隨訪對照觀察[J]. 中華醫學雜志, 2006, 82(12): 796-891.
14.	Donadio J, Grande J. IgA nephropathy[J]. N Engl J Med, 2002, 347(10): 738-748.
15.	Galla JH. IgA nephropathy[J]. Kidney Int, 1995, 47(2): 377-387.
16.	Zatz R, Noronha IL, Fujihara CK. Experimental and clinical rationale for use of MMF in nontransplant progressive nephropathies[J]. Am J Physiol Renal Physiol, 2002, 283(6): 1167-1175.
17.	Russo D, Pisani A, Balletta MM, et al. Additive antiproteinuric effect of converting enzyme inhibitor and Losartan in normotensive patients with IgA nephropathy[J]. Am J Kidney Dis, 1999, 33(5): 851-856.
18.	Samuels JA, Strippoli G FM, Craig J C, et al. Immunosuppressive agents for treating IGA nephropathy(Cochrane Review)[J]. Cochrane Database Syst Rev, 2003, (4): CD003965.
19.	Bennett WM, Walke RG, Kincaid-Smith P. Treatment of IgA nephropathy with eicosapentanoic acid: A two-year prospective trial[J]. Clin Nephrol, 1989, 31(3): 128-131.
20.	Pettersson EE, Rekola S, Berglund L, et al. Treatment of IgA nephropathy with omega-3 polysaturated fatty acids: a prospective, double-blind, randomised study[J]. Clin Nephrol, 1994, 41(4): 183-190.
21.	Donadio JV Jr, Bergstralh EF, Offord KP, et al. A controlled trial of fish oil in IgA nephropathy[J]. N Engl J Med, 1994, 331(18): 1194-1199.
22.	Donadio JV Jr, Larson TS, Bergstralh EJ, et al. A randomised trial of high dose compared with low dose omega-3 fatty acids in severe IgA nephropathy[J]. J Am Soc Nephrol, 2001, 12(4): 791-799.
23.	Dillon JJ. Fish oil therapy for IgA nephropathy. Efficacy and interstudy variability[J]. J Am Soc Nephrol, 1997, 8(11): 1739-1744.
24.	Nowack R, Birck R, Van der Woude FJ. Mycophenolate mofetil for systemic vasculitis and IgA nephropathy[J]. The Lancet, 1997, 349(9054): 774.
25.	Frisch G, Lin J L, Rosenstock J, et al. Mycophenolate mofetil (MMF) vs placebo in patients with moderately advanced IgA nephropathy: a double-blind randomized controlled trial[J]. Nephrol Dial Transplant, 2005, 20(10): 2139-2145.
26.	Tang S, Leung JC, Chan LY, et al. Mycophenolate mofetil alleviates persistent proteinuria in IgA nephropathy[J]. Kidney Int, 2005, 68(2): 802-812.
27.	王偉銘. KDIGO關于原發性腎小球腎炎的治療初步意見[J]. 中國醫學前沿雜志, 2011, 3(2): 18-21.
28.	Briggs WA, Choi MJ, Scheel PJ Jr. Successful mycophenolate mofetil treatment of glomerular disease[J]. Am J Kidney Dis, l998, 31(2): 2l3-217.
29.	Borrows R, Chusney G, James A, et al. Determinants of mycophenolic acid levels after renal transplantation[J]. Ther Drug Monit, 2005, 27(4): 442-450.
30.	Staatz CE, Tett SE, Clinical pharmacokinetics and pharmacodynamics of mycophenolate in solid organ transplant recipients[J]. Clin Pharmacokinet, 2007, 46(1): 13-58.
31.	Hesselink DA, van Hest RM, Mathot R, et al. Cyclosporine interacts with mycophenolic acid by inhibiting the multidrug resistance-associated protein2[J]. Am J Transplant, 2005, 5(5): 987-994.
32.	Lightstone L. Lupus nephritis: where are we now?[J]. Curr Opin Rheumatol, 2010, 22(3): 252-256.
33.	Yu ZC, Zhou PJ, Xu D, et al. Investigation on pharmacokinetics of mycophenolic acid in Chinese adult renal transplant patients[J]. Brit J Clin Pharmaco, 2006, 62(4): 446-452.
34.	Zhou PJ, Xu D, Yu ZC, et al. Pharmacokinetics of mycophenolic acid and estimation of exposure using multiple linear regression equations in Chinese renal allograft recipients[J]. Clin Pharmacokinet, 2007, 46(5): 389-401.
35.	Lu XY, Huang HF, Sheng TJ, et al. Pharmacokinetics of mycophenolic acid in Chinese kidney transplant patients[J]. J Zhejiang Univ Sci B, 2005, 6 (9): 885-891.
36.	Zheng CX, Liu ZH, Qin WS, et al. Moitoring of mycophenolic acid concentration for mycophenolate mofetil treatment in patients with glomerular diseases[J]. Chin Nephrol Dial Transplant, 2007, 16(5): 406-412.
37.	Van Gelder T, Hilbrands LB, Vanrenterghem Y, et al. A randomized double-blind, multicenter plasma concentration controlled study of the safety and efficacy of oral mycophenolate mofetil for the prevention of acute rejection after kidney transplantation[J]. Transplantation, 1999, 68(2): 261-266.

1. 　Luetscher Jr JA, Deming QB, Harvey J, et al. Treatment of nephrosis with cortisone[J]. J Clin Invest, 1950, 29(12): 1576-1587.
2. 　Vanderwoude FJ. Mycophenplate mofetil(RS 61443): nothing new under the sun or an important break-through in the field of transplantation? [J]. Nephrol Dial Transpl, 1995, 10(7): 1112-1115.
3. 　Huang YF, Liu ZH, Huang HD, et al. Effects of mycophenolic acid on endothelial cells[J]. Int Immunopharmacol, 2005, 5(6): 1029-1039.
4. 　Allison AC. Mechanisms of action of mycophenolate mofetil[J]. Lupus, 2005, 14(3): S2-S8.
5. 　Apple GB, Radhakrishnan J, Ginzler EM. Use of mycophenolate mofetil in autoimmune and renal diseases[J]. Transplantation, 2005, 80(2): S265-S271.
6. 　Mase BD, Oyen R, Claes K, et al. Mycophenolate mofetil in IgA nephropathy: Results of a 3-year prospective placebo-controlled randomized study[J]. Kidney Int, 2004, 65(5): 1842-1849.
7. 　Trinidad PR, Meza L, Diaz OA. Mycophenolate mofetil treatment in primary glomerular diseases without response to conventional immunosuppressive agents[J]. J Am Soc Nephrol, 2003, 14(7): 800-812.
8. 　Polenakovic M, Grcevska L, Dzikova S. Mycophenolate mofetil in treatment of idiopathic stages IIII-V membranous nephropathy[J]. Nephrol Dial Transpl, 2003, 18(6): 1233-1234.
9. 　D’Amcio G. Natural history of idiopathic IgA nephropathy: the role of clinical and histological prognostic factors[J]. Am J Kidney Dis, 2002, 36(2): 227-37.
10. 　Tang S, Tang A, Wong S, et al. Long–term study of mycophenolate mofetil treatment in IgA nephropathy[J]. Kidney Int, 2010, 77(6): 543-549.
11. 　Groth C, Pichlmayr R, Sadek S, et al. Placebo-controlled study of mycophenolate mofetil combined with cyclosporine and corticosteroids for prevention of acute rejection[J]. Lancet, 1995, 345(8961): 1321-1325.
12. 　Appel GB, Contreras G, Dooley MA, et al. mycophenolate mofetil versus cyclophosphamide for Induction Treatment of Lupus Nephritis[J]. J Am Soc Nephrol, 2009, 20(5): 1103-1112.
13. 　陳香美, 陳仆, 蔡廣研, 等. 麥考酚酸酯治療IgA 腎病的隨訪對照觀察[J]. 中華醫學雜志, 2006, 82(12): 796-891.
14. 　Donadio J, Grande J. IgA nephropathy[J]. N Engl J Med, 2002, 347(10): 738-748.
15. 　Galla JH. IgA nephropathy[J]. Kidney Int, 1995, 47(2): 377-387.
16. 　Zatz R, Noronha IL, Fujihara CK. Experimental and clinical rationale for use of MMF in nontransplant progressive nephropathies[J]. Am J Physiol Renal Physiol, 2002, 283(6): 1167-1175.
17. 　Russo D, Pisani A, Balletta MM, et al. Additive antiproteinuric effect of converting enzyme inhibitor and Losartan in normotensive patients with IgA nephropathy[J]. Am J Kidney Dis, 1999, 33(5): 851-856.
18. 　Samuels JA, Strippoli G FM, Craig J C, et al. Immunosuppressive agents for treating IGA nephropathy(Cochrane Review)[J]. Cochrane Database Syst Rev, 2003, (4): CD003965.
19. 　Bennett WM, Walke RG, Kincaid-Smith P. Treatment of IgA nephropathy with eicosapentanoic acid: A two-year prospective trial[J]. Clin Nephrol, 1989, 31(3): 128-131.
20. 　Pettersson EE, Rekola S, Berglund L, et al. Treatment of IgA nephropathy with omega-3 polysaturated fatty acids: a prospective, double-blind, randomised study[J]. Clin Nephrol, 1994, 41(4): 183-190.
21. 　Donadio JV Jr, Bergstralh EF, Offord KP, et al. A controlled trial of fish oil in IgA nephropathy[J]. N Engl J Med, 1994, 331(18): 1194-1199.
22. 　Donadio JV Jr, Larson TS, Bergstralh EJ, et al. A randomised trial of high dose compared with low dose omega-3 fatty acids in severe IgA nephropathy[J]. J Am Soc Nephrol, 2001, 12(4): 791-799.
23. 　Dillon JJ. Fish oil therapy for IgA nephropathy. Efficacy and interstudy variability[J]. J Am Soc Nephrol, 1997, 8(11): 1739-1744.
24. 　Nowack R, Birck R, Van der Woude FJ. Mycophenolate mofetil for systemic vasculitis and IgA nephropathy[J]. The Lancet, 1997, 349(9054): 774.
25. 　Frisch G, Lin J L, Rosenstock J, et al. Mycophenolate mofetil (MMF) vs placebo in patients with moderately advanced IgA nephropathy: a double-blind randomized controlled trial[J]. Nephrol Dial Transplant, 2005, 20(10): 2139-2145.
26. 　Tang S, Leung JC, Chan LY, et al. Mycophenolate mofetil alleviates persistent proteinuria in IgA nephropathy[J]. Kidney Int, 2005, 68(2): 802-812.
27. 　王偉銘. KDIGO關于原發性腎小球腎炎的治療初步意見[J]. 中國醫學前沿雜志, 2011, 3(2): 18-21.
28. 　Briggs WA, Choi MJ, Scheel PJ Jr. Successful mycophenolate mofetil treatment of glomerular disease[J]. Am J Kidney Dis, l998, 31(2): 2l3-217.
29. 　Borrows R, Chusney G, James A, et al. Determinants of mycophenolic acid levels after renal transplantation[J]. Ther Drug Monit, 2005, 27(4): 442-450.
30. 　Staatz CE, Tett SE, Clinical pharmacokinetics and pharmacodynamics of mycophenolate in solid organ transplant recipients[J]. Clin Pharmacokinet, 2007, 46(1): 13-58.
31. 　Hesselink DA, van Hest RM, Mathot R, et al. Cyclosporine interacts with mycophenolic acid by inhibiting the multidrug resistance-associated protein2[J]. Am J Transplant, 2005, 5(5): 987-994.
32. 　Lightstone L. Lupus nephritis: where are we now?[J]. Curr Opin Rheumatol, 2010, 22(3): 252-256.
33. 　Yu ZC, Zhou PJ, Xu D, et al. Investigation on pharmacokinetics of mycophenolic acid in Chinese adult renal transplant patients[J]. Brit J Clin Pharmaco, 2006, 62(4): 446-452.
34. 　Zhou PJ, Xu D, Yu ZC, et al. Pharmacokinetics of mycophenolic acid and estimation of exposure using multiple linear regression equations in Chinese renal allograft recipients[J]. Clin Pharmacokinet, 2007, 46(5): 389-401.
35. 　Lu XY, Huang HF, Sheng TJ, et al. Pharmacokinetics of mycophenolic acid in Chinese kidney transplant patients[J]. J Zhejiang Univ Sci B, 2005, 6 (9): 885-891.
36. 　Zheng CX, Liu ZH, Qin WS, et al. Moitoring of mycophenolic acid concentration for mycophenolate mofetil treatment in patients with glomerular diseases[J]. Chin Nephrol Dial Transplant, 2007, 16(5): 406-412.
37. 　Van Gelder T, Hilbrands LB, Vanrenterghem Y, et al. A randomized double-blind, multicenter plasma concentration controlled study of the safety and efficacy of oral mycophenolate mofetil for the prevention of acute rejection after kidney transplantation[J]. Transplantation, 1999, 68(2): 261-266.

Previous Article
The Clinical Research of Combined Stroke Unit in Elderly Patients
Next Article
Molecular Diagnosis of Mycobacterium Intracellulare Infection in Patients with Kidney Transplantation

West China Medical Journal

Treatment of IgA Nephrophy with Low-dose Mycophenolate mofetil and Steroid

Abstract Full text Figures/Tables Video References Cited by

Previous Article

Next Article

Format

Content